Qualigen Therapeutics Presents Data on QN-302 at AACR’s Pancreatic Cancer Meeting
Posters include data regarding 1) mode of action, and
2) preclinical toxicology
Related news for (QLGN)
- MoBot alert highlights: NASDAQ: VIOT, NASDAQ: GNTA, NASDAQ: QLGN, NASDAQ: VIVK, NASDAQ: ADTX (10/24/25 06:00 AM)
- MoBot’s Stock Market Highlights – 10/24/25 05:00 AM
- Today’s Top Performers: MoBot’s Market Review 10/24/25 04:00 AM
- Today’s Top Performers: MoBot’s Market Review 10/23/25 05:00 PM
- Qualigen Therapeutics Partners with BitGo to Execute First Multi-Asset C10 Treasury Allocation
